Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market Biotech company’s pneumococcal vaccine hit primary endpoints in late-stage study

Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market Biotech company’s pneumococcal vaccine hit primary endpoints in late-stage study https://www.statnews.com/2026/10/05/vaxcyte-pneumococcal-vaccine-study-pfizer-merck/ By Jason MastOct. 5, 2026 General Assignment Reporter